PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1552189 · Fiscal year ends 12/31
Financial factors as of 2023-03-31 (2023Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.7%
TTM net income YoY-3.7%
TTM EPS YoY-14.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—
Margins
Gross margin28.4%
Operating margin-288.0%
Net margin-443.5%
FCF margin-137.5%
EBITDA margin-196.4%
Returns
ROE-4,290.8%
ROA-39.8%
ROIC (approx.)-3,336.3%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets120.5%
Debt / equity—
Current ratio0.37x
Interest coverage-2.75x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-28.7%
Payout ratio—
Capex / revenue13.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.38M | $1.63M | $2.06M | $9.02M | $345,680 |
| Cost of revenue | $1.26M | $1.23M | $1.52M | $7.02M | $1.94M |
| Gross profit | $1.12M | $396,470 | $540,578 | $2.00M | -$1.70M |
| R&D expense | — | — | — | $0 | $22,100 |
| SG&A expense | $1.46M | $1.09M | $1.52M | $2.81M | $2.82M |
| Operating income | -$5.55M | -$5.65M | -$5.94M | -$5.26M | -$10.67M |
| Interest expense | $1.56M | $2.05M | $1.11M | $1.51M | $479,111 |
| Pretax income | -$8.02M | -$9.14M | -$4.78M | -$5.23M | -$10.02M |
| Net income | -$8.02M | -$9.14M | -$4.78M | -$5.23M | -$10.02M |
| EBITDA | -$3.83M | -$3.98M | -$4.26M | -$3.63M | -$10.61M |
| EPS (basic) | -0.48 | -0.62 | -0.28 | -0.31 | -0.30 |
| EPS (diluted) | -0.48 | -0.62 | -0.27 | -0.31 | -0.30 |
| Weighted avg. shares (diluted) | 16.63M | 14.86M | 17.82M | 16.92M | 33.90M |
| Balance sheet | |||||
| Cash & equivalents | $100,922 | $6,951 | $19,774 | $84,379 | $18,405 |
| Short-term investments | $14,933 | $1.11M | $3.79M | $2.85M | — |
| Receivables | $263,970 | $206,127 | $244,496 | $147,302 | $55,725 |
| Inventory | $4.01M | $4.45M | $4.26M | $8.41M | $1.34M |
| Current assets | $4.66M | $6.38M | $9.10M | $11.52M | $2.43M |
| PP&E, net | $6.45M | $7.68M | $8.84M | $13.59M | $477,433 |
| Goodwill | $3.01M | $2.19M | $2.19M | $2.19M | — |
| Intangibles | $3.01M | $2.19M | $61,401 | $122,801 | $2.15M |
| Total assets | $17.98M | $19.49M | $23.78M | $31.36M | $8.02M |
| Current liabilities | $19.45M | $15.07M | $10.07M | $18.26M | $3.81M |
| Short-term debt | — | — | — | $696,286 | $185,906 |
| Long-term debt | — | — | — | $335,510 | $185,906 |
| Total debt | — | — | — | $1.03M | $371,812 |
| Total liabilities | $26.27M | $21.63M | $16.68M | $24.65M | $4.13M |
| Shareholders' equity | -$8.29M | -$2.14M | $7.10M | $6.71M | $11.94M |
| Net debt | — | — | — | $947,417 | $353,407 |
| Shares outstanding | 17.65M | 14.97M | 14.07M | 16.92M | 43.82M |
| Cash flow statement | |||||
| Operating cash flow | -$1.52M | -$2.40M | -$3.92M | -$7.65M | -$5.75M |
| Capital expenditure | $65,322 | $243,804 | $162,946 | $3.20M | $541,203 |
| Free cash flow | -$1.59M | -$2.64M | -$4.09M | -$10.85M | -$6.29M |
| Investing cash flow | -$65,322 | -$196,972 | $522,533 | -$3.08M | -$2.04M |
| Financing cash flow | $1.68M | $2.58M | $3.33M | $2.30M | $7.80M |
| Depreciation & amortization | $1.71M | $1.67M | $1.68M | $1.63M | $63,770 |
| Stock-based compensation | — | — | — | $1.35M | $3.77M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.